MELANOMA

PROGRAM PUBLICATIONS

1. Witz, I.P., Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res, 2008. 100: p. 203-29.

2. Lee, J.H., et al., Biological Factors, Tumor Growth Kinetics, and Survival After Metastasectomy for Pulmonary Melanoma. Ann Surg Oncol, 2009.

3. Lotem, M., et al., Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res, 2009. 15(15): p. 4968-77.

4. Witz, I.P., The Tumor Microenvironment: The Making of a Paradigm. Cancer Microenviron, 2009.

5. Berger, M.F., et al., Integrative analysis of the melanoma transcriptome. Genome Res, 2010. 20(4): p. 413-27.

6. Davis, I.J., et al., Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res, 2010. 70(2): p. 639-45.

7. Deng, W.G., et al., IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res, 2010.

8. Izraely, S., et al., Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol Lett, 2010. 130(1-2): p. 107-14.

9. Koyanagi, K., et al., Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res, 2010. 16(8): p. 2402-8.

10. Levy, C., et al., Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell, 2010. 141(6): p. 994-1005.

11. Li, Y., et al., MART-1--specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol, 2010. 184(1): p. 452-65.